Related Experiment Videos
[Diagnostic strategies in Hepatitis C virus infection]
1Disciplina de Microbiologie, Facultatea de Medicina, Universitatea de Medicină şi Farmacie Gr.T. Popa Iaşi.
Insights
Hepatitis C virus (HCV) infection affects 170 million globally, with significant risks of chronic hepatitis, cirrhosis, and liver cancer. This review covers advanced diagnostic tests for HCV, including ELISA, RIBA, and RT-PCR, aiding in disease management.
Area of Science:
- Hepatology
- Virology
- Immunology
Context:
- Hepatitis C virus (HCV) is a leading cause of chronic viral hepatitis worldwide.
- An estimated 170 million people are infected globally, with high rates of progression to chronic hepatitis, cirrhosis, and liver cancer.
- HCV was identified and characterized in 1989, spurring the development of diagnostic tools.
Purpose:
- To review the current state-of-the-art diagnostic tests and assays for Hepatitis C virus infection.
- To highlight advancements in detecting HCV antibodies and RNA for diagnosis and management.
Summary:
- Diagnostic advancements include enzyme-linked immunosorbent assays (ELISA) and recombinant immunoblot assays (RIBA) with enhanced sensitivity and specificity for HCV antibodies.
- Reverse-transcriptase polymerase chain reaction (RT-PCR), both qualitative and quantitative, enables tracking of HCV natural history and therapy monitoring.
- These tests are crucial for the accurate diagnosis and effective management of HCV infection.
Impact:
- Improved diagnostic accuracy leads to earlier detection and intervention for HCV.
- Effective monitoring of HCV infection and treatment response facilitates better patient outcomes.
- Advances in HCV diagnostics contribute to the global strategy for viral hepatitis control and elimination.
Abstract:
Hepatitis C virus (HCV) is the most common cause of chronic viral hepatitis. The World Health Organization estimates that 170 million people world-wide are infected with HCV; 70% of them will develop chronic hepatitis and 20-30% cirrhosis in 10-30 years. Of those with cirrhosis, an estimated 25-30% will develop liver cancer. Since the identification and molecular characterization of HCV in 1989, a variety of diagnostic tests based on the detection of hepatitis virus antibodies or HCV RNA in the serum have been developed. The enzyme-linked immunosorbent assays (ELISA 3) and the recombinant immunoblot assays (RIBA 2nd and 3rd generation) exhibit improved sensitivity and specificity for HCV antibodies. Qualitative and quantitative reverse-transcriptase polymerase chain reaction (RT-PCR) has allowed clinicians to track the natural history of HCV and to monitor the progress of therapy. This article reviews the state-of-the-art tests and assays developed for the diagnosis and management of HCV infection.